ISRCTN71826974 https://doi.org/10.1186/ISRCTN71826974

BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma (NHL)

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 18/10/2018	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
RADIATION

Study information

Scientific Title
BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma (NHL)

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lymphoma (non-Hodgkin's)

Interventions
Standard radiotherapy versus low dose radiotherapy

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date

30/04/1997

Completion date
31/12/2005

Eligibility

Key inclusion criteria
1. Any patient receiving local radiotherapy (RT) where the aim of the treatment is local control of that lymphoma, whether as radical treatment of Stage I disease, consolidation therapy after chemotherapy or palliation
2. Histological diagnosis of NHL
3. Aged 18 years or over
4. Able to give informed consent

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
1000

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
30/04/1997

Date of final enrolment
31/12/2005

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
British National Lymphoma Investigation (BNLI) (UK)

Sponsor details
CRC and UCL Cancer Trials Centre
222 Euston Road
London
United Kingdom
NW1 2DA
+44 (0)20 7679 8060
bnli@ctc.ucl.ac.uk

Sponsor type
Charity

Website
http://www.bnli.ucl.ac.uk

Funder(s)

Funder type
Charity

Funder Name
British National Lymphoma Investigation (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results				No	Yes